ALIVUS — Alivus Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹127.53bn
- IN₹119.95bn
- IN₹25.52bn
Annual cashflow statement for Alivus Life Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | C2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 5,649 | 6,286 | 6,313 | 6,541 | 7,513 |
| Depreciation | |||||
| Non-Cash Items | 331 | 25.3 | 258 | 201 | 405 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -383 | -3,672 | -2,970 | -3,433 | -3,018 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 5,976 | 3,060 | 4,135 | 3,915 | 5,654 |
| Capital Expenditures | -1,322 | -1,628 | -1,290 | -1,662 | -3,071 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 99.4 | 161 | 125 | -4,495 | -2,631 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1,222 | -1,467 | -1,165 | -6,156 | -5,702 |
| Financing Cash Flow Items | -0.72 | -5.47 | -15.5 | -24.1 | -53.7 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -788 | -3,876 | -2,794 | -62.3 | -643 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3,966 | -2,283 | 176 | -2,304 | -691 |